MTRAC has now has a new website and this page is no longer being updated. 

Go to new MTRAC website.

Midlands Therapeutics Review & Advisory Committee

 
‌

Independent review of medicines for primary care

MTRAC is an independent professional committee of prescribers and other key decision-makers in the use of medicines in primary care. The purpose of the Committee has been to review selected pharmaceutical products to assess their clinical value, safety and suitability for use in primary care in the West Midlands Region, and to support appropriate prescribing. From 2010, the Committee also provides support to commissioners, by addressing the financial implications of the use of new drugs and practical issues affecting decisions on commissioning, in addition to the clinical evidence for efficacy and safety. Specific questions that are relevant for commissioning decisions concerning individual drugs or drug classes, such as emerging concerns about safety, are also addressed.

The membership of the Committee and process for review are described in the MTRAC Constitution.

The opinions and recommendations of the Committee, and the evidence considered in the assessments, are summarised in summary sheets. When use with a shared care agreement is recommended for a particular drug, a template ESCA (Effective Shared Care Agreement) is provided that can be modified for local use. These documents are available on the website MTRAC Commissioning Support Summary Sheets & ESCAs. An annual booklet summarising all MTRAC guidance is available.

Latest activities of MTRAC are listed on the latest news page. Viewers can also register to receive an electronic bulletin listing latest MTRAC activities with links to new summary sheets.